-
Deucravacitinib, sold
under the
brand name Sotyktu, is a
medication used for the
treatment of moderate-to-severe
plaque psoriasis. It is a
tyrosine kinase...
-
inflammatory conditions,
primarily plaque psoriasis.
Brepocitinib Deucravacitinib Martin G (February 2023). "Novel
Therapies in
Plaque Psoriasis: A Review...
- as JAK1,
which is
hoped to give it an
improved side
effect profile.
Deucravacitinib Leit S,
Greenwood J,
Carriero S,
Mondal S, Abel R,
Ashwell M, et al...
- and TYK2, and was
developed for the
treatment of
plaque psoriasis.
Deucravacitinib Zasocitinib Fensome A,
Ambler CM,
Arnold E,
Banker ME,
Brown MF, Chrencik...
- of tetrabe****ne,
which had been
approved earlier for the same use.
Deucravacitinib is a
deuterated JAK
inhibitor (specifically, TYK2 inhibitor) approved...
- L04AF04
Filgotinib L04AF05
Itacitinib L04AF06
Peficitinib L04AF07
Deucravacitinib L04AF08
Ritlecitinib L04AG01 Muromonab-CD3 L04AG02
Efalizumab L04AG03...
-
especially chronic inflammation involved in the
development of cancer.
Deucravacitinib Kavanagh ME,
Horning BD,
Khattri R, Roy N, Lu JP,
Whitby LR, et al...
-
approved for the use in
active psoriatic arthritis. The TYK2
inhibitor deucravacitinib (Sotyktu),
which has been
approved for
plaque psoriasis, is currently...
-
safety and
efficacy of
icotrokinra compared with both
placebo and
deucravacitinib in moderate-to-severe
plaque psoriasis.
Icotrokinra was
jointly discovered...
-
original on 10
September 2022.
Retrieved 10
September 2022. "Sotyktu (
deucravacitinib) Tablets, for Oral Use. Full
Prescribing Information" (PDF). Bristol-Myers...
